An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer

Journal of Clinical Pharmacology

Volumn 45, Issue 11, 2005, Pages 1245-1249

  Dineen, Martin K ^a   Tierney, David S ^b   Kužma, Petr ^b   Pentikis, Helen S ^c  

^a Atlantic Urological Associates   (United States)

^b Valera Pharmaceuticals   (United States)

^c ICON Development Solutions   (United States)

Author keywords

Histrelin; Implant; Pharmacodynamics; Pharmacokinetics; Prostate cancer

Indexed keywords

HISTRELIN; TESTOSTERONE;

AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRUG RELEASE; EVALUATION; HUMAN; HYDROGEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; UNITED STATES;

AGED; AGED, 80 AND OVER; DRUG IMPLANTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYDROGELS; LUTEINIZING HORMONE; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 27244433714     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005281043     Document Type: Article

References (13)

1. Denmeade SR, Isaacs JT. Development of prostate cancer treatment: the good news. Prostate. 2004;58:211-224.
2. Marks LS. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. Urology. 2003;62:36-42.
3. Huggins C, Hodges CV. Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol. 2002;168:9-12.
4. Walsh PC. Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am. 1975;2:125-140.
5. Kozlowski JM, Grayhack JT. Carcinoma of the prostate. In: Gillenwater JY, Grayhack JT, Howards SS, Duckett JW, eds. Adult and Pediatric Urology, Vol. 2, Chicago, London, Boca Raton: Year Book Medical Publishers; 1987:1126-1219.
6. Byar DP. Proceedings: the Veterans Administration Cooperative Urological Group studies of carcinoma of the prostate: a review. Cancer Chemother Rep. 1975;59:225-227.
7. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988;7:165-170.
8. Labrie F, Dupont A, Belanger A, Lachance R. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol. 1987;138:804-806.
9. Labrie F, Dupont A, Belanger A, Emond J, Monfette, G. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci USA. 1984;81:3861-3863.
10. Schulze H, Senge T. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol. 1990;144:934-941.
11. Ascoli M, Segaloff DL. Adenohypophyseal hormones and their hypothalamic releasing factors. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman?s The Pharmacological Basis of Therapeutics. 9th ed. New York, New York: McGraw Hill; 1996:1363-1382.
12. Kiesewetter J, Salem SA, Cisar L, Petrone M. Long-term Efficacy and Safety of a Hydrogel Implant Containing Histrelin Acetate, a Synthetic Luteinizing Hormone Releasing Hormone Agonist, in Patients with Prostate Cancer. Eatontown, New Jersey: Roberts Pharmaceutical Corporation; 2000. Clinical Study Report: Protocol BAR-002-0591A-USA.
13. Roland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. Philadelphia, Penn: Lea and Febiger; 1989.